Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.46 |
| ▸ | TOP2A known ✓ | P11388 | 1/20 | 0.40 |
| ▸ | TOP2B known ✓ | Q02880 | 1/20 | 0.40 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.34 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.34 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205947 | 0.97 | ACHE (0.48) | ACHETOP2ATOP2BTSHRMAOA | |
| SCHEMBL1172624 | 0.91 | ACHE (0.48) | ACHETOP2ATOP2BTSHRMAOA | |
| SCHEMBL19078822 | 0.81 | LOXL2 (0.40) | ACHETOP2ATOP2BTSHRKDM4E | |
| SCHEMBL4936785 | 0.81 | ACHE (0.67) | ACHETOP2ATOP2BKDM4ECASP6 | |
| SCHEMBL18407678 | 0.81 | ACHE (0.40) | ACHETOP2ATOP2BTSHRKDM4E | |
| SCHEMBL23429131 | 0.79 | ACHE (0.39) | ACHETOP2ATOP2BTSHRKDM4E | |
| SCHEMBL15651082 | 0.79 | ACHE (0.39) | ACHETOP2ATOP2BKDM4ECASP6 | |
| SCHEMBL3074715 | 0.79 | CYP3A4 (0.55) | ACHETOP2ATOP2BTSHRKDM4E | |
| SCHEMBL790120 | 0.79 | ACHE (0.39) | ACHETOP2ATOP2BKDM4ECASP6 | |
| SCHEMBL17064613 | 0.79 | CYP4F2 (0.44) | ACHETOP2ATOP2BMAOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081737-A1 | POND REACTOR FOR RECOVERY OF METALS | CYCAD GROUP, LLC | 2022-03-17 | — | — | US | disclosed |
| US-20210340025-A1 | Compositions and Methods for Purification of Metals from Steel Making Waste Streams | CYCAD GROUP, LLC | 2021-11-04 | — | — | US | disclosed |
| EP-3853177-A1 | COMPOSITIONS AND METHODS FOR PURIFICATION OF METALS FROM STEEL MAKING WASTE STREAMS | Lixivia, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-113165897-A | Compositions and methods for purifying metals from steelmaking waste streams | 里克希维亚有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020131958-A1 | POND REACTOR FOR RECOVERY OF METALS | Lixivia, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20180223392-A1 | COMPOSITIONS AND METHODS FOR RECOVERY OF ALKALINE METALS | CYCAD GROUP, LLC | 2018-08-09 | — | — | US | disclosed |
| US-8088941-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2012-01-03 | — | — | US | disclosed |
| US-20080312188-A1 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-12-18 | — | — | US | disclosed |
| US-20080176889-A1 | 9-anilinoacridine alkylating agents | ACADEMIA SINICA (TW) | 2008-07-24 | — | — | US | disclosed |
| US-7378432-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-05-27 | — | — | US | disclosed |
| EP-1824468-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Tel Aviv University Future Technology Development L.P. (IL) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006054298-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2006-05-26 | — | — | WO | disclosed |
| US-20060069066-A1 | 3-(4-(3-guanidinophenyl)-1,2,3-triazol-1-yl)benzyl phosphoric acid hydrochloride; obesity, non-insulin dependent diabetes mellitus, insulin-dependent condition, affective disorder, neurodegenerative diseases, psychotic disease; compounds having hydrophobic moiety to a terminus of a peptide GSK-3 | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. | 2006-03-30 | — | — | US | disclosed |
| US-6750223-B2 | TO INHIBIT THE GROWTH OF A VARIETY OF TUMOR/CANCER CELLS, ESPECIALLY LEUKEMIA, COLON, MELANOMA, AND BREAST CANCER CELLS | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2004-06-15 | — | — | US | disclosed |
| US-20040072856-A1 | 4-ANILINO[2,3-b]QUINOLINE DERIVATIVES,THEIR PREPARATION PROCECC ANDPHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2004-04-15 | — | — | US | disclosed |
| US-6072046-A | SELECTIVELY FORM TRIPLEXES WITH A COMPLEMENTARY TARGET SEQUENCE IN DOUBLE-STRANDED DNA AND EFFICIENTLY CROSSLINK WITH BOTH STRANDS; THERAPEUTICS, DIAGNOSTICS, AND GENETIC PROBES | EPOCH PHARMACEUTICALS, INC. (US) | 2000-06-06 | — | — | US | disclosed |
| WO-2000012523-A1 | DIAZIRIDINYL-ARYL AND BIS-[DI(CHLOROETHYL)AMINO]-ARYL OLIGONUCLEOTIDE CONJUGATES AND REAGENTS FOR MAKING THE SAME | EPOCH PHARMACEUTICALS, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
| US-5939428-A | ANTITUMOR AGENTS AND ANTIGROWTH AGENTS FOR CELLS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 1999-08-17 | — | — | US | disclosed |
| US-5354864-A | Antitumor agents | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1994-10-11 | — | — | US | disclosed |
| WO-1993023049-A1 | 3-(9-ACRIDINYLAMINO)-5-HYDROXYMETHYLANILINE DERIVATIVES AS ANTICANCER AGENTS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069066-A1 | 3-(4-(3-guanidinophenyl)-1,2,3-triazol-1-yl)benzyl phosphoric acid hydrochloride; obesity, non-insulin dependent diabetes mellitus, insulin-dependent condition, affective disorder, neurodegenerative diseases, psychotic disease; compounds having hydrophobic moiety to a terminus of a peptide GSK-3 | GSK3A, GSK3B, PYGB | ACHE 2318/4885TOP2A 4652/4885TOP2B 4485/4885 |
| US-20040072856-A1 | 4-ANILINO[2,3-b]QUINOLINE DERIVATIVES,THEIR PREPARATION PROCECC ANDPHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ADRA2C, CYP4B1, NQO2 | ACHE 301/4885TOP2A 1561/4885TOP2B 908/4885 |
| US-20080312188-A1 | Glycogen synthase kinase-3 inhibitors | GSK3B, GSK3A, GSKIP | ACHE 1890/4885TOP2A 1587/4885TOP2B 1572/4885 |
| US-20080176889-A1 | 9-anilinoacridine alkylating agents | BCL9, MCL1, BCL9L | ACHE 2396/4885TOP2A 5/4885TOP2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.